Programm                 "Degeneration und Regeneration– Grundlagen, Diagnostik und Therapie"


Hotelbuchung
   Hotel Registration
Grußwort
   Welcome address
Beteiligte Gesellschaften
   Societies involved
DOG Information
   DOG Information
Eröffnung des Kongresses
   Opening Ceremony
Preise
   Awards
Ablauf der Tagung 2003
   General overview of congress
Lageplan der Räumlichkeiten
   Map of Congress Center
Wissenschaftliche Themen
   Scientific topics
Symposien
   Symposia
Wissenschaftliches Programm
   Scientific program
Posterpräsentationen
   Poster Presentation
Kurse
   Courses
Begleitende Veranstaltungen
   Accompanying program
Arbeitssitzungen
   Working sessions
Rahmenprogramm
   Social program
Allgemeine Informationen
   General Information
Autorenindex
   Index of Authors
Industrieaussteller
   Commercial exhibitors
Sponsoren
   Sponsors
Impressum



DOG Homepage


Abstract
Abstract

Stargardt Disease – A Disease Entity? Clinical and Molecular Genetic Perspectives

Kellner U.1, Weber B. H. F.2
1Augenklinik, Univ.-Klinikum Benjamin Franklin, Freie Universität Berlin, 2Institut für Humangenetik, Abt. für Humangenetik, Biozentrum, Würzburg

Purpose: Stargardt disease was first described in 1909 by Karl Stargardt. Since then multiple clinical classifications have been developed. The association with mutations in the ABCA4 gene was noted by Allikmets et al in 1997.
Method: Analysis of the recent literature and own findings in patients with Stargardt disease.
Results: Stargardt disease is the most frequent inherited macular dystrophy. Onset is usual within the first two decades of life, however, it may occur later in the 3rd to 5th decade of life. The most frequent recessive form is associated with mutations in the ABCA4 gene. Mutations in the same gene are also associated with cone dystrophies, retinitis pigmentosa and potentially with age-related macular degeneration. The ABCA4 gene encodes a transport protein in the vitamin A cycle. The severity of disease expression most likely depends on the degree of residual activity of the mutated transporter. Histopathologic findings and knock out mouse models provided novel insight into pathophysiologic processes and potential therapeutic strategies.
Conclusions: Due to the high variability of clinical expression in ABCA4-associated disorders the term Stargardt disease may not longer be appropriate for diagnostic purposes. The combi


Zurück | Back